News

In a recent study entitled “Accuracy of invasive arterial pressure monitoring in cardiovascular patients: an observational study” the authors suggest that when evaluating a patient’s cardiovascular system, a non-invasive blood pressure measurement may be more accurate than the standard invasive method to measure arterial pressure. Improved…

The Baltimore Walk for Hope is an upcoming event organized by the Pulmonary Hypertension Association (PHA) to raise awareness about pulmonary hypertension. The event will take place next Sunday, November 2nd at the Baltimore Zoo. The event is designed to be a 1.1 mile family and friendly walk…

Naturally occurring microRNA molecules (miRNA) hold the potential to be a new treatment for pulmonary artery disease. A group at Sookmyung University and Yale University led by Professor Kim Jong-min investigated the causes of pulmonary arterial hypertension and discovered new molecular mechanism contributing to the disease. “Our research is…

A pair of nurses from the Stanford University Medical Center are set to conduct a live webinar on much-needed public awareness of clinical research — the most crucial and intensive phase in product and treatment development before achieving marketing approval and finally benefiting consumers and patients everywhere.

At the Max Planck Institute for Heart and Lung Research in Bad Nauheim and Giessen University, a team of scientists under the leadership of Dr. Soni Savai Pullamsetti is uncovering potential reasons why pulmonary arteries become narrowed and lead to pulmonary hypertension. Recent experiments, highlighted in a…

To date, twelve therapies have been approved to treat pulmonary arterial hypertension (PAH). Of these, three were approved last year, indicating significant progress in understanding and treating PAH. These advancements were greatly needed, as according to the recent publication of “Pulmonary Arterial Hypertension: Progress and Challenges in…

The Pulmonary Hypertension Association (PHA) has launched a new campaign to raise attention about pulmonary hypertension (PH), called PHAware. The main purpose of the campaign is to reach the general public, news media, and potential donors in order to expand their exposure, both nationally and internationally. One of the…

A 2011 study entitled, “Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study” identified the fact that prevalence of heart failure with preserved ejection fraction is increasing in the patient population, and that patient prognosis worsens among those…